(2S)-4-(4-methylphenyl)-5-(2H-tetrazol-5-yl)-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-6-one

In Stock•Starting at $626 for 2 mg•Purity ≥ 99%

CAS No.	1441057-15-3
MDL No.	N/A
MF	C₂₄H₂₁F₆N₅O₂
MW	525.40
InChI Key	AEMPUAWUDAMJBV-QFIPXVFZSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability
2 mg	To Be Confirmed	$626	In Stock
10 mg	99%	$2853	In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	1441057-15-3
Product Name	(2S)-4-(4-methylphenyl)-5-(2H-tetrazol-5-yl)-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-6-one

Associated Conditions

non-alcoholic fatty liver disease

* The information provided here is compiled from public sources and is for reference only.

(2S)-4-(4-methylphenyl)-5-(2H-tetrazol-5-yl)-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-6-one

In Stock•Starting at $626 for 2 mg•Purity ≥ 99%

CAS No.	1441057-15-3
MDL No.	N/A
MF	C₂₄H₂₁F₆N₅O₂
MW	525.40
InChI Key	AEMPUAWUDAMJBV-QFIPXVFZSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability
2 mg	To Be Confirmed	$626	In Stock
10 mg	99%	$2853	In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	1441057-15-3
Product Name	(2S)-4-(4-methylphenyl)-5-(2H-tetrazol-5-yl)-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-6-one

Associated Conditions

non-alcoholic fatty liver disease

* The information provided here is compiled from public sources and is for reference only.

(2S)-4-(4-methylphenyl)-5-(2H-tetrazol-5-yl)-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-6-one

Pricing & Availability

Product Information

Biological Profile

Properties

Associated Conditions

Documentation

(2S)-4-(4-methylphenyl)-5-(2H-tetrazol-5-yl)-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-6-one

Pricing & Availability

Product Information

Biological Profile

Properties

Associated Conditions

Documentation

(2S)-4-(4-methylphenyl)-5-(2H-tetrazol-5-yl)-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-6-one

Pricing & Availability

Product Information

Biological Profile

Properties

Associated Conditions

Related Articles

MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity.

Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders.

Documentation

(2S)-4-(4-methylphenyl)-5-(2H-tetrazol-5-yl)-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-6-one

Pricing & Availability

Product Information

Biological Profile

Properties

Associated Conditions

Related Articles

MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity.

Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders.

Documentation